Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

[1][2] Ponezumab was developed by Pfizer Inc.

In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.

[3] This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This drug article relating to the nervous system is a stub.